The global human immunodeficiency virus type 1 (HIV 1) market size is expected to reach a valuation of USD 34.83 Billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6% from 2023 to 2033.
HIV is a virus that targets the body's cells that aid in the battle against infectious disease, making the individual more sensitive to other illnesses and infections. HIV is a retrovirus comprising RNA rather than DNA. It attacks the immune system (T lymphocytes and other white blood cells with CD4 receptors on their surfaces) in the body.
According to the Institute for Health Metrics and Evaluation, the market's expansion can be attributed to the rising incidence rate of HIV-1 infection, which, unlike the fatality rate from this viral illness, has not updated significantly over the years. It affected approximately 37 million individuals around the world. Moreover, only half of this population has access to antiretroviral therapeutic interventions for disease control. HIV-1 is the more frequent of the two varieties of the human immunodeficiency virus, accounting for roughly 96% of all infections worldwide. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 34.83 Billion |
| Anticipated Forecast Value (2033) | USD 62.37 Billion |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
The global population of individuals infected with this virus rapidly increased during the historical period. As a result of the lack of sufficient diagnosis and treatment infrastructure, the disease has heavily impacted poor and developing countries on a wide scale. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.6%.
The incidence of HIV is soaring at an alarming rate. Based on the World Health Organization (WHO), a guesstimated 33.0 million people are infected with HIV. This has resulted in higher public awareness, which is leading to a rise in test methods. Over the forecast period, this will result in an increase in demand for HIV medicines with higher efficacy for the treatment and care of the disease.
Burgeoning HIV/AIDS Incidence to Push Market Growth
One of the key contributing factors expected to propel market growth is the rising prevalence of HIV/AIDS, particularly in Africa. According to the World Health Organization (WHO), an estimated 33.0 million people were living with HIV infection in 2021, with 1.5 million [1.1 million-2.0 million] new HIV infections.
According to WHO, women and girls constituted 54% of all HIV-positive people. This large patient population in various regions is driving up demand for antiretroviral (ARV) drugs. Furthermore, the government is working to improve HIV-1 patients' access to treatment and assessment. This is expected to fuel the global HIV-1 market.
Combined efforts of the government and several NGOs to propel the market growth
The deliberate initiatives of the government and multiple NGOs to supply at-risk individuals with better exposure to disease diagnosis and treatment for infected patients are key factors driving the HIV-1 market growth.
Numerous companies, including Cipla, Inc. and Gilead Sciences, Inc., have also implemented diagnosis education programs to lessen the detrimental ramifications of infectious diseases. The potential growth of this market is heavily reliant on the unfulfilled assessment and treatment needs in African and Asian countries.
Scarcity of Treatment Access and Lack of awareness of HIV Infection Status May Stifle Growth
Despite advances in technology development, enhanced scientific knowledge of HIV, and the affordability of therapeutic approaches, some detaining aspects are reducing future growth. Many individuals who are HIV-positive or at risk of becoming HIV-positive are unable to get timely treatment access. Besides that, there is no treatment for this virus.
As reported by the Joint United Nations Program on HIV/AIDS (UNAIDS), for instance, diagnosis metrics are distributed unevenly around the world. The lack of sufficient treatment options continues to be a challenge in middle-income and emerging nations, stifling the expansion of the HIV1 market.
North America's dominance is due to the high prevalence of HIV infection
With a market share of USD 21 Billion in 2022, North America dominated the market. This region's dominance is credited to the rising incidence of HIV infection in the US citizenry. Based on a study performed by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people were living with HIV at the end of 2018.
With such a large patient population, the requirement for HIV drugs skyrockets. The population's consciousness is another aspect that contributes to regional growth. Furthermore, the presence of prominent players providing new HIV medications for the treatment of HIV1 transmission would augment the market growth.
Because of its dense population, the Asia Pacific market is the fastest-growing region
Owing to the highly populous nations, like China and India, with a huge proportion of HIV patients, the Asia Pacific market is predicted to be the fastest-growing market with the largest CAGR over the forecast period. Moreover, the vast number of therapeutic interventions and financial support from the private sector and medical companies are expected to propel the industry.
For example, Gilead Sciences, Inc., one of the world's biggest antiretroviral drug manufacturers, declared a USD 1.4 Million funding for its 'Gilead Asia Pacific Rainbow Grant Program' in Asia Pacific in December 2020. The program consists of Gilead's initiative to strengthen public-private collaborations in the Asia Pacific region in order to tackle the difficulties posed by HIV-infected patients.
Integrase inhibitors are preferred as first-line treatments for recently diagnosed patients
As the primary line of treatment for HIV, the integrase inhibitors segment held the second-highest market share in 2021, supporting the growth of the segment. Integrase inhibitors are advised as initial treatments for newly diagnosed HIV infection by the International AIDS Society (IAS).
The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment has the smallest share of the market due to significantly fewer requirements for this drug class compared to the late innovative pharmaceutical launches
Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc, Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 34.83 Billion |
| Anticipated Forecast Value (2033) | USD 62.37 Billion |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Mexico, Germany, UK, France, Spain, Italy, Russia, China, Japan, India, South Korea, Australia, Saudi Arabia, South Africa, UAE, Israel |
| Key Companies Profiled | AbbVie Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Inc.; Genentech Inc.; Gilead Sciences, Inc.; Merck & Co. Inc.; ViiV Healthcare; GlaxoSmithKline; Sanofi |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 5: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 9: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 3: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 4: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 5: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 9: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 10: Global Market Attractiveness by Region, 2023 to 2033
Figure 11: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 12: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 13: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 14: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 15: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 16: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 17: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 18: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 19: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 20: North America Market Attractiveness by Country, 2023 to 2033
Figure 21: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 23: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 24: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 25: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 26: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 27: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 28: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 29: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 30: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 31: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 32: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 33: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 34: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 35: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 36: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 37: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 38: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 39: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 40: Europe Market Attractiveness by Country, 2023 to 2033
Figure 41: Asia Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 43: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 44: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 45: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 46: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 47: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 48: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 49: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 50: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 51: Middle East and Africa Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 52: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 53: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 54: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 55: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 56: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 57: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 58: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 59: Middle East and Africa Market Attractiveness by Drug Class, 2023 to 2033
Figure 60: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
FMI projects the global Human Immunodeficiency Virus Type 1 (HIV 1) market to expand at a 6% value CAGR by 2033.
The global Human Immunodeficiency Virus Type 1 (HIV 1) market is estimated at a market value of USD 34.83 Billion.
The global Human Immunodeficiency Virus Type 1 (HIV 1) market is expected to garner a market value of USD 62.37 Billion
FMI has projected Asia Pacific to be one of the key regions for the Human Immunodeficiency Virus Type 1 (HIV 1) market.
AbbVie, Inc, Boehringer, Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline and Sanofi.
Explore Similar Insights
Human Immunodeficiency Virus Type 1 (HIV 1) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
